Product
VK-2019
2 clinical trials
3 indications
Indication
Nasopharyngeal CarcinomaIndication
Nasopharyngeal CancerIndication
Epstein-Barr Virus Related CarcinomaClinical trial
Phase 1/2a Open Label, Multicenter Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer, With Pharmacokinetic and Pharmacodynamic Correlative StudiesStatus: Terminated, Estimated PCD: 2020-06-23
Clinical trial
Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative StudiesStatus: Recruiting, Estimated PCD: 2025-02-01